Stellaromics, founded in 2022 and based in Boston, is advancing biomedical research with patented technology that deciphers intricate 3D transcription and translation patterns in native biological tissue. Their flagship product, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), reveals gene expression patterns within intact tissue, aiding in the identification of treatment targets and supporting biomedical research. Stellaromics is in late-stage product development on its Plexa™ suite of products, designed to enable researchers and clinicians to create detailed cellular maps for enhanced disease understanding.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/06/23 | $25,000,000 | Series A |
Plaisance Capital Management | undisclosed |
